WeVote
Log In

Bill

Bill

HB 3176

Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.

89th Legislature (2025) Introduced by Ben Bumgarner and 17 co-sponsors

Texas bill establishing state regulatory framework for mRNA-based communicable disease products, potentially duplicating or conflicting with federal pharmaceutical oversight.

Referred to Public Health
#health--general(i0385) #health--otherdiseases&medicalconditions(i0383) #immunizations(s4341) #medicine&prescriptiondrugs(s7338)
0
WeVote Research Nonpartisan
Bill Summary · HB 3176

Legislative bill overview

HB 3176 establishes regulatory oversight for products manufactured, sold, and distributed using mRNA technology specifically for communicable disease prevention or treatment in Texas. The bill creates a framework governing how these products—primarily vaccines—are developed, marketed, and distributed within the state. This represents state-level intervention in pharmaceutical regulation, an area traditionally overseen by federal agencies like the FDA.

Why is this important

mRNA vaccine technology has become a significant public health tool, particularly following COVID-19 vaccine development. Establishing separate state regulations could either create additional safety standards or create parallel regulatory pathways that conflict with federal oversight, affecting vaccine availability, pricing, and distribution networks. The bill signals Texas's intent to exercise greater control over emerging biotechnology products.

Potential points of contention

  • Federal versus state authority: Pharmaceutical manufacturing and interstate commerce are primarily federal jurisdictions; state-level regulations may conflict with FDA authority and interstate commerce principles
  • Innovation and market access: Additional state requirements could slow vaccine development, increase costs, or discourage manufacturers from operating in Texas, potentially limiting access to new mRNA treatments
  • Public health uniformity: Differing state standards could fragment vaccine distribution and create confusion about product safety, undermining coordinated disease prevention efforts

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.